Cartalax peptide: cell studies and human evidence limits

Cartalax is a name used for the AED tripeptide. The sources discussed here include chondrocyte senescence research, a study of chondrogenic markers in cultured human mesenchymal stem cells, and a review that mentions oral use in older patients. Human-derived cells in a laboratory are not patients in a clinical trial; keep those evidence types separate.

Correction, October 1, 2026: an earlier version missed PMID 37782646 and incorrectly said no study connected AED with chondrogenic markers or reported a cell-culture concentration. This correction checks the PubMed abstract. The full paper and the broader clinical and regulatory claims still need review.

What the evidence covers

Cartalax is the commercial name for the AED tripeptide, part of a family of short synthetic peptide bioregulators to come out of a Russian research program built around a small circle of gerontology researchers.

The strongest verified finding comes from a 2023 paper by Myakisheva and colleagues on chondrocyte aging. They characterized the senescence-associated secretory phenotype (SASP) that forms in aging chondrocytes: rising p16, p21 and p53, rising pro-inflammatory cytokines TNF-alpha and IL-1alpha, and falling Sirt1. Treating chondrocytes with the AED peptide, alongside a comparator called the cartilage polypeptide complex, normalized that pattern ^[1].

6 senescence markers reported normalized by the AED peptide (Cartalax) in chondrocyte experiments PMID 37356100

That is a real, specific, citable result. It is also not a clinical trial. A cultured chondrocyte’s protein levels shifting in a dish is not the same claim as a person’s joint pain improving.

The human claim sits somewhere else entirely: a separate 2023 review, also written by Myakisheva and colleagues, states that the AED tripeptide has shown “high efficacy in animal models of OA” and describes “oral administration in patients with OA of older age groups” ^[2]. That is the entire human evidence base the indexed literature offers. A summary clause inside someone else’s review, with no trial name, no patient count, no comparator group, and no design attached to it.

Bottom line: the one sentence in the literature that puts Cartalax and human patients in the same breath names no study behind it. You cannot look it up, because it was never described well enough to find.

Cell-level results are not human results

The chondrocyte paper reports cellular findings, while the separate review summarizes research. Another 2023 experiment examined chondrogenic markers in cultured human mesenchymal stem cells. These cell-culture observations do not by themselves establish a clinical benefit in patients.

What that design cannot do is tell you whether the same peptide, injected or swallowed by a person, reaches cartilage tissue at a concentration high enough to do anything. A chondrocyte bathed directly in a peptide solution and a chondrocyte sitting inside a joint capsule, behind synovial fluid and a wall of cartilage matrix, face two different exposure problems. Nothing in this record addresses the second one.

What the chondrogenic-marker study reports

A 2023 study reports that AED increased gene expression and protein synthesis for SOX9, aggrecan, type II collagen and COMP in cultured human mesenchymal stem cells during replicative aging ^[3]. The earlier claim that no indexed study connected AED with these markers was incorrect. This was a laboratory study, not a trial of Cartalax treatment in patients.

Key gap: a study of chondrogenic markers exists, but its cell-culture findings do not establish cartilage repair or pain relief in people. This correction does not validate vendor percentage claims.

When assessing a vendor claim, compare its stated model, measurement and effect with the cited experiment. The PubMed abstract reports changes in cultured cells; it does not supply a clinical treatment effect. A source for a cellular finding does not establish the same result for a marketed product used by a person.

The same laundering shows up with GHK-Cu, where topical-trial data gets quietly repurposed to back injectable products the trials never tested. The mechanism differs in each case. The move, borrowing credibility from a real result to cover a claim the literature never made, doesn’t.

Cell-culture concentrations are not human doses

The AED mesenchymal-stem-cell study does report a laboratory concentration in its abstract ^[3]. The earlier statement that no citable cell-culture concentration existed was incorrect. An experimental culture concentration is not a human dose or an administration schedule.

The second gap is the one that matters if you are the one taking it. Every dose posted on a vendor page or a forum thread is a guess, because the dose-ranging study that would tell anyone what an effective or safe human dose looks like has not been run, let alone published.

Safety: reported by nobody, tested by nobody

• No adverse event data. No published study reports tolerability or a safety profile for Cartalax in humans.
• No regulatory review. Vendors selling Cartalax label it “not for human consumption,” the standard disclaimer that lets a research-chemical seller sidestep the manufacturing and safety oversight that applies to an actual drug.
• No interaction data. Nobody has studied Cartalax alongside other bioregulator peptides or standard osteoarthritis medications, so interaction risk is simply unknown.

What already has trial data that Cartalax doesn’t

• Structured resistance training, backed by decades of controlled human trials.
• Intra-articular corticosteroid injection for osteoarthritis flares.
• Hyaluronic acid injection, studied and debated in enough trials to have a real argument about effect size.

These options carry a documented effect, even a modest or contested one. Choosing an unstudied peptide with cell-culture evidence over any of them trades that documented effect for a research-chemical brand name. For a broader look at which peptide-marketing claims do have trial support behind them, see Natural Peptides: Which Claims Have Human Trials.

What would change this picture

A registered human trial, run outside the small circle of researchers who currently write about this compound, measuring a real cartilage or pain outcome, would be the first result that moves Cartalax past cell culture. Until one exists, “cartilage bioregulator” remains a marketing category here rather than a clinical one.

The entire human claim for Cartalax rests on one unsourced sentence, on one shelf, written by one small group.

Verdict: Cartalax may eventually earn a place next to the interventions above, but it hasn’t yet, and buying it now is a bet that cell-culture findings, written by the people who developed it, will someday be replicated by someone with no stake in the answer.

This article is for research and informational purposes only and is not intended to diagnose, treat, cure, or prevent any disease. The peptides discussed here are sold for research use only and are not for human consumption. Nothing in this article constitutes medical advice. Consult a qualified clinician before making changes to a health, training, or supplementation protocol.